Stansky Michael P
SEC Form 4 insider trading activity
Stansky Michael P has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: May 18, 2026.
On the most recent filing, Stansky Michael P is listed as Director at TriSalus Life Sciences, Inc. Inside the rolling window, Stansky Michael P reported 2 open-market purchases totaling $3.0M in TLSI and no open-market sales. The largest disclosed transaction in the window is a purchase of 610,000 TLSI shares on May 15, 2026, worth $1.5M.
Companies traded
Other insiders at TLSI
Insider Buying
$3.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Stansky Michael P made?
Stansky Michael P has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does Stansky Michael P trade?
Stansky Michael P has filed SEC Form 4 disclosures for 1 company, including TLSI.
When was Stansky Michael P's most recent SEC Form 4 filing?
Stansky Michael P's most recent SEC Form 4 filing on Tracefour is dated May 18, 2026.
What is Stansky Michael P's total buy and sell value in the current window?
Inside the rolling retention window, Stansky Michael P bought $3.0M and sold $0 based on SEC Form 4 filings.
What was Stansky Michael P's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 610,000 TLSI shares on 2026-05-15, worth $1.5M, per SEC Form 4 filings.